Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.



from The Medical News http://ift.tt/1zR9qCB